Heylen, A.; Vermeiren, Y.; Kema, I.P.; van Faassen, M.; van der Ley, C.; Van Dam, D.; De Deyn, P.P.
Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. Pharmaceuticals 2023, 16, 615.
https://doi.org/10.3390/ph16040615
AMA Style
Heylen A, Vermeiren Y, Kema IP, van Faassen M, van der Ley C, Van Dam D, De Deyn PP.
Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. Pharmaceuticals. 2023; 16(4):615.
https://doi.org/10.3390/ph16040615
Chicago/Turabian Style
Heylen, Annelies, Yannick Vermeiren, Ido P. Kema, Martijn van Faassen, Claude van der Ley, Debby Van Dam, and Peter P. De Deyn.
2023. "Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD" Pharmaceuticals 16, no. 4: 615.
https://doi.org/10.3390/ph16040615
APA Style
Heylen, A., Vermeiren, Y., Kema, I. P., van Faassen, M., van der Ley, C., Van Dam, D., & De Deyn, P. P.
(2023). Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. Pharmaceuticals, 16(4), 615.
https://doi.org/10.3390/ph16040615
